^
Association details:
| Biomarker: | TMB-H + PD-L1 expression |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) + Imjudo (tremelimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tumor mutation burden (TMB), PD-L1, IFN-? signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)
Published date:
09/30/2019
Excerpt:
Study 10/NCT02261220 was a phase I trial including 190 2L UC pts treated with D (20 mg/kg Q4W) +T (1 mg/kg Q4W)...In Study 10, TMB and PD-L1 double positive pts (n = 14, 24%) had best OS and pts low in both had worst (n = 19, 32%, HR = 0.23, p = 0.01).
DOI:
10.1093/annonc/mdz253
